COMPANY PROFILE

Saccharo

Explore full profile

Biotech start-up in the stealth mode, in pursuit of a novel oncology target found only on cancer cells

Oakland, United StatesFounded 2017Biotech & Life Sciences

Valuation $50–100M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Saccharo

Saccharo is a preclinical-stage biotechnology company focused on the development of cancer therapies. The company's main area of research is immuno-oncology, where it is pioneering a new approach to cancer treatment by targeting a novel polysaccharide-based immune shielding pathway. This pathway is believed to play a crucial role in protecting cancer cells from the body's immune system.

The company's business model revolves around the research and development of a pipeline of therapeutic products aimed at treating cancer and other novel diseases. By focusing on a specific biological mechanism, Saccharo aims to develop targeted treatments that can overcome the limitations of current therapies. The company serves the oncology market, with its primary clients being patients and healthcare providers in the cancer treatment sector.

Saccharo has raised a total of $7.38 million in funding from three investors in a single funding round. This capital is being used to advance its drug candidates through the preclinical stages of development, with the ultimate goal of obtaining regulatory approval and bringing its products to market.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Oakland, United States
Employees: 6
Open positions: None listed
Dealroom signal: 76.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Sep 2022	$11M	$43M	Undisclosed	↗
CONVERTIBLEOther financing	Jun 2021	$0	—	Sand Hill Angels	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Saccharo website traffic

Latest recorded traffic for Saccharo is 260 monthly website visits, down 69.4% over the last three months. Saccharo's team grew 20% over the past year.

Latest monthly visits260 3-month web change-69.4% 1-year team growth+20%

Monthly website visitsNov 2022–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BTBrink TherapeuticsUnlocking in vivo cell therapy with the next generation of gene editing technology	Saint-Mandé, France	Operational	12	$3.9M	$15M
ETEvolving TherapeuticsPhage-based solutions to combat bacteria	Paterna, Spain	Operational
ATAer TherapeuticsClinical-stage biopharmaceutical company developing inhaled treatments for muco-obstructive lung diseases	San Francisco, United States	Operational
INInnoSkelA pioneering biotechnology company developing therapies for rare skeletal diseases	Valbonne, France	Operational
4P4P Pharma4P-Pharma \| Translating Science to Product	Lille, France	Operational
IGIgyxosInnovative pharmaceutical products for human reproductive health	Nouzilly, France	Operational
ACActipulseActipulse International specializes in the diagnostic and treatment of neurological and psychiatric pathologies	Cambridge, United States	Operational
DIDiamanteA national company that specializes in cleaning and maintenance services	Verona, Italy	Operational